Concorde Medical Group PLLC

Concorde Clinical Trials

Concorde Medical Group actively conducts clinical research that includes a wide range of medical conditions.

If you fit the eligibility criteria listed or have a question about our Clinical Trials Program, contact us by email .(JavaScript must be enabled to view this email address) or contact us directly at (212)889 5544. Don’t see a study you think you qualify for? Contact us to be added to our mailing list.

We are currently working on the following clinical trials:

If you are interested in Clinical Trial participation or have any questions, please contact either of our Clinical Research Coordinators:

Juanita Jones or Lily Alaj

(212) 889 5544

.(JavaScript must be enabled to view this email address)


IBS-D in Women (Sponsored by Menarini):

This is a 52 week, double blind, randomized, placebo-controlled, parallel-group Phase III study with re-randomised at week 25 to evaluate the efficacy and safety of oral Ibodutant 10 MG once daily in FEMALE patients with irritable bowel syndrome with diarrhea. We are looking for female patients 18 years or older with SEVERE IBS-D. Ibodutant is a tachykinin NK2 receptor antagonist. Patients must be able to complete a daily phone diary for the duration of the study.

Clostridium Difficile (Sponsored by Actelion):

This is a multi-center, randomized, double-blind study, to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).

You may be eligible to participate in this research study if you meet the following criteria:

  • We are looking for male or female patients over 18 years of age.
  • Patients must be diagnosed with mild-moderate OR severe CDAD (first occurrence or first recurrence within 3 months) with diarrhea,
  • Experience a change in bowel habits with > 3 liquid or unformed bowel movements (UBM) within 24 hours prior to randomization.
  • Patients must have a positive C. difficile toxin test on a stool sample produced within 72 hours prior to randomization.

Ulcerative Colitis Registry Study (Sponsored by AbbVie):

The purpose of this study is to evaluate the long-term safety of HUMIRA in moderately to severely active UC adult patients, 18 years of age and older, who are treated as recommended in the local product label. Patients being prescribed and treated with IMM (6-mercaptopurine (6-MP) or azathioprine (AZA)) with no concurrent biologic use will be considered the reference group.

This is a registry study. We are being asked to follow enrolled patients during regular office visits at intervals determined by routine clinical practice. Patients will be asked to complete four brief quality of life surveys during each standard of care visit.


Clostridium Difficile (Sponsored by Merck)

This is a Phase 3, Double-Blind, Placebo-Controlled study to test the efficacy of a single infusion of Human Monoclonal Antibody to Clostridium difficile toxin A, toxin B, or both toxins A&B in addition to standard of care therapy.

Patients are eligible to participate if they have been diagnosed with Clostridium difficile and treated with standard of care within 1 week of study entry. We are looking for men and women who are 18 and older.

Hepatitis C (Sponsored by Beckman Coulter)

This is an observational study evaluating the Beckman Coulter DxN HCV viral load assay in the management of HCV-infected individuals undergoing antiviral therapy. Patients who are 18 and older and have Hepatitis C genotypes 1,2, and 3 are eligible to participate. Two extra tubes of blood will be taken at regularly scheduled visits.


If you are interested in Clinical Trial participation or have any questions, please contact either of our Clinical Research Coordinators:

Juanita Jones or Lily Alaj

.(JavaScript must be enabled to view this email address)

In This Section

Concorde Medical Group
232 E. 30th St.
New York, NY 10016
Telephone: (212) 889-5544
Fax: (212) 481-1089

Dr. Alex Sherman
Director of Clinical Research
(212) 889-5544 ext 165

Juanita Jones
Clinical Research Coordinator
(212) 889-5544 ext 152

Lily Alaj
Clinical Research Coordinator
(212) 889-5544 ext 154

or Contact Us